---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-105175"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:43:48.534527+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# enGene Q3 net loss $14.1M; cash $257.7M; LEGEND data expected Sept 2024

## Summary
- Net loss $14.1M ($0.32/share) vs $6.0M prior year; operating expenses $16.8M (up from $6.2M).
- Cash and equivalents $257.7M; expects runway into 2027.
- Preliminary LEGEND study data (BCG-unresponsive NMIBC) due by end of September 2024.
- Ron Cooper appointed CEO and board member; Dr. Raj Pruthi promoted to CMO in July 2024.

## SEC filing metadata
- accession: 0000950170-24-105175
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017024105175/0000950170-24-105175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024105175/engn-20240910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-105175
- JSON: https://secwatch.observer/filing/0000950170-24-105175.json
- Plain text: https://secwatch.observer/filing/0000950170-24-105175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.